Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies
Sign Up to like & getrecommendations! Published in 2018 at "RMD Open"
DOI: 10.1136/rmdopen-2018-000749
Abstract: Objective To evaluate the magnitude of response to secukinumab treatment over 3 years in patients with ankylosing spondylitis (AS) grouped by baseline C-reactive protein (CRP) levels in a pooled study of two pivotal phase III… read more here.
Keywords: baseline reactive; response; ankylosing spondylitis; response secukinumab ... See more keywords
Predictors of response to secukinumab in patients with psoriatic arthritis and axial manifestations: a post-hoc analysis of the MAXIMISE trial
Sign Up to like & getrecommendations! Published in 2022 at "RMD Open"
DOI: 10.1136/rmdopen-2022-002303
Abstract: Objectives To investigate patient characteristics predictive of response to secukinumab in patients with psoriatic arthritis (PsA) with axial manifestations. Methods In a post-hoc analysis from the MAXIMISE trial (NCT02721966) in patients with PsA and axial… read more here.
Keywords: response; secukinumab patients; response secukinumab; axial manifestations ... See more keywords